HHS Peptide Enforcement Discretion Policy (October 2026): Six Peptides, Ten Conditions

The notice (Federal Register document 2026-22192, RIN 0910-ZD94) announces the availability of an "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances", signed by HHS Secretary Robert F. Kennedy Jr. Comments can be filed for two weeks after publication on regulations.gov under docket HHS-OASH-2026-0496.

The wording explains why press coverage alternates between "draft" and "interim": the notice announces a draft policy, and the policy itself describes an interim approach that applies until FDA rulemaking decides whether each peptide belongs on the 503A bulks list. It is explicitly non-binding, creates no rights, and HHS reserves the right to revisit it in whole or in part if a safety signal or product-quality problem emerges.

Appendix B of the policy fixes the identity of each substance – salt form, molecular formula, molecular weight and sequence – and limits the routes of administration within scope. Identity here includes the counter-ion: the policy names acetate salts for five peptides and the free base for Semax, which is why salt form is no longer a footnote on a certificate of analysis.

Enforcement discretion applies only when all of the following are present, summarised from the policy text:

• The peptide is on the interim access list in Appendix A.
• It has the identity and route limitations described in Appendix B (sequence, structure, molecular weight and formula).
• The bulk substance comes from an FDA-registered facility and has a valid certificate of analysis with test results consistent with FDA's guidance-based criteria.
• The original manufacturer – not a repacker or distributor – is registered with FDA, complies with CGMP, and its physical location is on the COA; repackers must validate the manufacturer and its COA.
• The compounder reports products made, serious adverse events and product-quality issues to FDA (MedWatch) and to the relevant States.
• The label states "This is a compounded drug product. Not for resale."
• The product contains a single active ingredient from Appendix A – no blends.
• Oral products require documentation that the formulation achieves adequate oral bioavailability in humans.
• The only device packaged with the product is an FDA 510(k)-cleared syringe.
• Everything else in the FD&C Act still applies, including sanitary conditions and the patient-specific prescription requirement.

• It is not an FDA approval and says nothing about efficacy.
• It does not place the peptides on the 503A bulks list; that still requires rulemaking, which may add some, all or none of them.
• It applies only to State-licensed pharmacies, Federal facilities and licensed physicians under section 503A. Outsourcing facilities under section 503B, research-chemical sellers and supplement brands are outside its scope.
• It does not cover multi-peptide blends; each product may contain one listed peptide only.
• It can be withdrawn at any time.

The policy is unusually direct about its purpose. HHS says the limited enforcement discretion is meant to discourage "the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers" that pose a safety risk, and to give patients a more controlled alternative. For the research-peptide market this cuts both ways: it gives no legal cover to products labelled for research use only, and it sets out in writing what a regulator considers an adequate certificate of analysis for these six substances.

That benchmark is the most practical part of the document for anyone reading a COA. Appendix B lists about twenty quality attributes – from net peptide content and nitrosamines to residual TFA and bacterial endotoxins – which we break down in a separate guide to the HHS COA requirements.

The policy runs against the recommendation of FDA's own scientific reviewers, who advised against listing each peptide; HHS's justifications in Appendix B argue that new characterisation data and documented use answer CDER's concerns. Critics, including an opinion piece in BioSpace, argue that bypassing the approval pathway weakens the incentive to develop these molecules properly. Supporters frame the policy as patient access with safeguards.

• Will FDA rulemaking follow the advisory committee, or the agency's scientific staff?
• How will States, which regulate pharmacies, apply the policy?
• Will MedWatch reporting under condition 5 produce enough data to detect safety signals?
• What happens to the five peptides scheduled for the next advisory-committee review?

ChemVerify's public test archive contains independently commissioned Janoshik Analytical reports for all six substances on the HHS list. Set against Appendix B, they show what a research-market lab report typically covers – identity, purity, quantity and, where commissioned, endotoxins and heavy metals – and which attributes the federal benchmark adds.

The policy does not approve BPC-157. It means HHS does not intend to take enforcement action against 503A compounding of BPC-157 acetate when all ten conditions are met. The status of products sold as research chemicals is unchanged.

BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon, each in the salt form and routes named in Appendix B of the policy.

No. It covers compounding by State-licensed pharmacies, Federal facilities and licensed physicians under section 503A. HHS describes research-use-only peptides from foreign manufacturers as the risk it wants to reduce.

DSIP was reviewed at the July 2026 advisory committee meeting but was the only one of the seven peptides the committee did not recommend for the 503A bulks list.

Until FDA rulemaking addresses each peptide in a final rule, unless HHS revises or withdraws it earlier – for example after a safety signal or a quality problem.

Yes. Comments could be submitted for two weeks after the 30 October 2026 publication via regulations.gov, docket HHS-OASH-2026-0496.